- Home
- SIGA vs CGEM Comparison
SIGA vs CGEM Comparison
Compare SIGA & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGA
- CGEM
- Stock Information
- Founded
- SIGA 1995
- CGEM 2016
- Country
- SIGA United States
- CGEM United States
- Employees
- SIGA N/A
- CGEM N/A
- Industry
- SIGA Biotechnology: Pharmaceutical Preparations
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- SIGA Health Care
- CGEM Health Care
- Exchange
- SIGA Nasdaq
- CGEM Nasdaq
- Market Cap
- SIGA 515.1M
- CGEM 482.7M
- IPO Year
- SIGA 1997
- CGEM 2021
- Fundamental
- Price
- SIGA $6.46
- CGEM $7.67
- Analyst Decision
- SIGA
- CGEM Strong Buy
- Analyst Count
- SIGA 0
- CGEM 6
- Target Price
- SIGA N/A
- CGEM $28.17
- AVG Volume (30 Days)
- SIGA 328.2K
- CGEM 298.9K
- Earning Date
- SIGA 08-05-2025
- CGEM 08-11-2025
- Dividend Yield
- SIGA 9.22%
- CGEM N/A
- EPS Growth
- SIGA N/A
- CGEM N/A
- EPS
- SIGA 0.67
- CGEM N/A
- Revenue
- SIGA $120,330,310.00
- CGEM N/A
- Revenue This Year
- SIGA N/A
- CGEM N/A
- Revenue Next Year
- SIGA $95.31
- CGEM N/A
- P/E Ratio
- SIGA $9.70
- CGEM N/A
- Revenue Growth
- SIGA N/A
- CGEM N/A
- 52 Week Low
- SIGA $4.95
- CGEM $6.85
- 52 Week High
- SIGA $12.83
- CGEM $19.89
- Technical
- Relative Strength Index (RSI)
- SIGA 42.33
- CGEM 44.23
- Support Level
- SIGA $6.97
- CGEM $8.07
- Resistance Level
- SIGA $7.32
- CGEM $8.59
- Average True Range (ATR)
- SIGA 0.21
- CGEM 0.39
- MACD
- SIGA -0.07
- CGEM 0.01
- Stochastic Oscillator
- SIGA 7.53
- CGEM 19.53
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.